UCSF Industry Partnerships

UCSF sees our industy collaborators as critical to our commitment to translate research into applications that improve the lives of individuals world-wide. We have a number of excellent partners with collaborations spanning basic, translational and clinical research and development.

Contact Us to explore partnership models and how your team can work with UCSF researchers.

UCSF Industry Partners

UCSF and Pfizer, Center for Therapeutic Innovation (CTI) have formed partnerships to accelerate the translation of biomedical research into effective new therapies for patients. The collaboration is designed to foster broad collaboration and exchange between UCSF and Pfizer scientists to help identify promising biologic and small molecule therapies, and quickly move them into proof-of-concept studies and clinical trials. See our biologics and small molecule press releases.


Sanofi, Inc and UCSF have formed several collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The collaborations include an oncology partnership that focus on project-based collaborations to accelerate the progression of research through the clinical proof of concept stage, as well as partnerships that promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation. See our press releases here and here on some of these collaborations.


Samsung Electronics Co., Ltd., and UCSF are partnering to accelerate validation and commercialization of promising new sensors, algorithms, and digital health technologies for preventive health solutions. The partnership establishes the UCSF-Samsung Digital Health Innovation Lab, a first-of-its-kind test bed where entrepreneurs and innovators will be able to validate their technologies and accelerate the adoption of new preventive health solutions. See our press release.

The UCSF Helen Diller Family Comprehensive Cancer Center and Onyx Pharmaceuticals, Inc (subsidiary of Amgen) have created the Oncology Innovation Alliance (OIA), a public-private partnership focusing on the discovery and development of novel therapies and their potential role in treating various types of hematologic cancers and solid tumors. See our press release.